BrainStorm Therapeutics establishes patent portfolio related to AI-powered drug discovery platforms using brain organoid disease models
Client(s) BrainStorm Therapeutics, Inc.
Jones Day is representing BrainStorm Therapeutics, Inc. in the establishment of a global patent portfolio related to drug discovery platforms powered by artificial intelligence (AI) and machine learning (ML) and the development of breakthrough medicines for complex neurological disorders by integrating human patient iPSC-derived brain organoid disease models, biomarker-based screening, and cutting-edge computational tools of deep learning and network medicine.